查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2088848

肌萎縮側索硬化症治療市場：2026-2032年全球市場預測（依療法、類型、治療階段、給藥途徑、治療策略、病患年齡層、照護環境和分銷管道分類）

Amyotrophic Lateral Sclerosis Treatment Market by Treatment, Type, Treatment Stage, Route of Administration, Line Of Therapy Strategy, Patient Age Group, Care Setting, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，肌萎縮側索硬化症 (ALS) 的治療市場將成長至 1,253.38 億美元，複合年成長率為 7.38%。

主要市場統計數據
基準年 2025 7.6113億美元
預計年份：2026年 8.1608億美元
預測年份：2032年 1,253,380,000 美元
複合年成長率 (%) 7.38%

肌萎縮側索硬化症 (ALS) 治療市場概覽

肌萎縮側索硬化症 (ALS) 的治療正從以症狀管理為主轉向精準神經病學。這包括使用緩解疾病藥物、呼吸護理、營養管理、行動支持、溝通支持以及多學科診療，所有這些都圍繞著可衡量的患者療效進行協調。 ALS 是進行性運動神經元疾病，症狀出現後患者的典型存活期為 2-5 年，但疾病進展速度有顯著差異，部分患者的存活期遠長於此。

肌萎縮側索硬化症治療前景的變革性變化

肌萎縮側索硬化症（ALS）的治療格局正因基因定義的亞型、生物標記主導的臨床試驗以及監管機構對嚴重神經退化性疾病快速核准流程日益成長的關注而發生重塑。 SOD1型ALS治療藥物的核准凸顯了標靶分子層面發病機製而非將ALS視為單一同質疾病的臨床和商業性重要性。

人工智慧對漸凍症治療的累積影響

人工智慧在肌萎縮側索硬化症（ALS）的治療中發揮越來越重要的作用，其應用領域涵蓋診斷、臨床試驗受試者招募、數位表現型分析和生物標記發現等。機器學習模型可以分析電子健康記錄、語音記錄、穿戴式感測器數據、影像資料、基因組分析以及呼吸功能指標，從而識別僅靠定期臨床評估無法捕捉到的疾病進展模式。

主要區域洞察：亞太地區、北美地區、歐洲、拉丁美洲、中東和非洲

北美在ALS治療藥物的引進方面主導，這得益於其完善的神經肌肉疾病中心、活躍的患者登記系統、對孤兒藥的優先核准以及積極參與臨床試驗。美國仍然是ALS已通過核准治療藥物、輔助技術、多學科診療以及患者權益倡導主導的研究經費的核心地區。另一方面，加拿大受益於其全民健保體系和專科醫生網路，但各省的報銷時間可能會影響治療藥物的可及性。

主要集團概況：七國集團、歐盟、金磚國家、東協、海灣合作理事會、北約

七國集團（G7）在肌萎縮側索硬化症（ALS）治療創新方面繼續發揮核心作用。這是因為美國、加拿大、日本、德國、法國、義大利和英國擁有先進的監管體系、臨床實驗室基礎設施、神經肌肉疾病中心以及針對高成本孤兒藥的保險報銷管道。北約成員國與此創新中心高度重合，為更廣泛的神經系統研究網路、數據共用舉措、復健技術的應用以及先進醫療服務的協調標準做出了貢獻。

主要ALS治療市場的關鍵國家洞察

美國擁有全球最具影響力的ALS治療環境，這得益於孤兒藥政策、《加速ALS關鍵療法獲取法案》、大型學術研究中心、臨床實驗室網路以及由患者權益倡導者主導的資金籌措。加拿大緊隨其後，擁有強大的神經肌肉護理網路和公共醫療保險體系。同時，墨西哥和巴西正透過公共和私人神經科醫療保健服務改善ALS的治療可近性，但先進的治療方案仍然高度依賴保險覆蓋範圍、專家資源和診斷基礎設施。

肌萎縮側索硬化症治療產業領導者使用的實用建議

產業領導者應優先考慮基於基因型分層的研發項目、檢驗的生物標記以及以患者為中心的終點指標，這些指標應反映患者的功能、生存期、語言能力、呼吸狀況、看護者負擔和生活品質。與肌萎縮側索硬化症（ALS）登記處、學術神經肌肉疾病中心、臨床實驗室網路和患者權益倡導組織建立合作關係，可以改善受試者的招募、保留率、基因檢測的可及性以及真實世界數據（REW）的品質。

ALS治療市場分析調查方法

本執行摘要基於監管機構、公共衛生機構、同行評審的神經病學文獻、臨床實驗室註冊庫、治療指南以及經認證的ALS患者支持和研究機構提供的檢驗信息，並採用系統的二手資料和分析研究途徑編寫而成。關鍵佐證包括治療核准情況、疾病流行病學、孤兒藥框架、臨床實驗室趨勢、基因檢測的相關性、生物標記開發以及區域醫療保健服務可近性指標。

結論：ALS治療創新的未來

隨著精準醫療、人工智慧驅動的研究和多學科診療的融合，肌萎縮側索硬化症（ALS）的治療市場正迎來一個關鍵的轉折點。儘管ALS仍然是一種毀滅性且進展迅速的疾病，但近期的進展表明，基因靶向干預、生物標記主導的研發以及綜合支持性護理有望重塑ALS的治療創新格局。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 肌萎縮側索硬化症治療市場：依治療方法分類

  • 藥物類型
    • Edaravone
    • Riluzole
  • 治療方法
    • 基因治療
    • 幹細胞療法

第8章 肌萎縮側索硬化症治療市場：依類型分類

  • 遺傳性肌萎縮性側索硬化症
  • 散發性肌萎縮性側索硬化症

第9章 肌萎縮側索硬化症治療市場：依治療階段分類

  • 初始治療
  • 中期治療
  • 後期治療

第10章 肌萎縮側索硬化症治療市場：依給藥途徑分類

  • 鞘內給藥
  • 靜脈
  • 口服

第11章 肌萎縮側索硬化症治療市場：依治療策略分類

  • 一線治療
  • 標靶治療
  • 二線治療/支持治療

第12章 肌萎縮側索硬化症治療市場：依患者年齡層別分類

  • 青少年和成年早期發病
  • 遲髮型

第13章 肌萎縮側索硬化症治療市場：依護理環境分類

  • 住院病人
  • 門診診所和醫院
  • 專科診所
    • 多學科ALS診所
    • 神經科專科診所
  • 居家醫療

第14章 肌萎縮側索硬化症治療市場：依分銷管道分類

  • 線上
  • 離線

第15章 肌萎縮側索硬化症治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第16章 肌萎縮側索硬化症治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 肌萎縮側索硬化症治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第19章：公司簡介

  • Tanabe Pharma Corporation
  • Biogen Inc.
  • Novartis AG
  • Amylyx Pharmaceuticals, Inc.
  • Dewpoint Therapeutics, Inc.
  • Zydus Lifesciences Limited
  • Sun Pharmaceutical Industries Ltd
  • Otsuka Pharmaceutical Co., Ltd.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Cipla Limited
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline PLC
  • AB Science SA
  • Alector, Inc.
  • Apotex Inc.
  • Aquestive Therapeutics, Inc.
  • AstraEureka Pharmaceuticals
  • BrainStorm Cell Limited
  • CorestemChemon Inc.
  • Coya Therapeutics, Inc.
  • Cytokinetics, Incorporated
  • DR. REDDY'S LABORATORIES LIMITED
  • Genervon Biopharmaceuticals, LLC
  • Implicit Bioscience Ltd.
  • Ionis Pharmaceuticals, Inc.
  • ITF Pharma, Inc.
  • Kringle Pharma, Inc.
  • Neurimmune AG
  • ONO PHARMACEUTICAL CO., LTD.
  • Orion Corporation
  • Orphazyme A/S
  • Pfizer, Inc.
  • Treeway BV
Product Code: MRR-AD36CD897F1B

The Amyotrophic Lateral Sclerosis Treatment Market is projected to grow by USD 1,253.38 million at a CAGR of 7.38% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 761.13 million
Estimated Year [2026] USD 816.08 million
Forecast Year [2032] USD 1,253.38 million
CAGR (%) 7.38%

Amyotrophic Lateral Sclerosis Treatment Market Overview

Amyotrophic lateral sclerosis treatment is moving from primarily symptom management toward precision neurology, where disease-modifying drugs, respiratory care, nutrition, mobility support, communication support, and multidisciplinary clinics are coordinated around measurable patient outcomes. ALS is a progressive motor neuron disease with a typical survival of 2-5 years after symptom onset, although progression varies widely and a subset of patients live much longer.

The current treatment landscape is anchored by approved therapies such as riluzole, edaravone, and tofersen for SOD1-ALS, alongside noninvasive ventilation, gastrostomy support, speech-generating technology, rehabilitation, and palliative care. With approximately 5,000 new ALS diagnoses reported annually in the United States and global prevalence commonly reported at about 4-6 cases per 100,000 people, the market remains highly specialized, clinically urgent, and closely linked to rare disease innovation.

Transformative Shifts in the ALS Treatment Landscape

The ALS treatment landscape is being reshaped by genetically defined subgroups, biomarker-led trials, and a stronger regulatory focus on accelerated pathways for serious neurodegenerative diseases. The approval of a therapy for SOD1-ALS underscored the clinical and commercial importance of targeting molecular drivers rather than treating ALS as a single homogeneous condition.

Transformative shifts also include decentralized trial models, remote respiratory monitoring, digital speech and movement assessments, and expanded use of real-world evidence. Developers are increasingly investing in antisense oligonucleotides, neuroinflammation modulation, mitochondrial pathways, RNA biology, and gene-targeted approaches. These changes are improving trial design, patient stratification, and evidence generation in a disease where small populations and rapid progression historically constrained drug development.

Cumulative Impact of Artificial Intelligence on ALS Treatment

Artificial intelligence is increasingly influencing ALS treatment across diagnosis, trial recruitment, digital phenotyping, and biomarker discovery. Machine learning models can analyze electronic health records, speech recordings, wearable sensor outputs, imaging, genomics, and respiratory metrics to identify progression patterns that may not be visible through periodic clinical assessments alone.

The cumulative impact of AI is most evident in clinical development efficiency. AI-enabled patient matching can help identify eligible participants for rare genetic subtypes, while predictive analytics can support adaptive trial designs and reduce variability in outcome measurement. In care delivery, AI-assisted communication tools, voice banking, and remote monitoring platforms are improving continuity of care, although validation, privacy protection, bias control, and clinical oversight remain essential.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East & Africa

North America leads ALS treatment adoption due to established neuromuscular centers, active patient registries, orphan drug incentives, and strong participation in clinical trials. The United States remains a core environment for approved ALS medicines, assistive technologies, multidisciplinary care, and advocacy-driven research funding, while Canada benefits from universal healthcare access and specialist networks, though provincial reimbursement timing can influence therapy uptake.

Europe shows strong clinical research capacity across Germany, France, Italy, Spain, and the United Kingdom, with European Union regulatory harmonization supporting cross-border studies, rare disease collaboration, and centralized medicine evaluation. Asia-Pacific is expanding through Japan's long-standing experience with intravenous edaravone, China's neurology infrastructure growth, India's improving diagnostic capacity, South Korea's advanced biopharma ecosystem, and Australia's active rare disease research environment. Latin America, the Middle East, and Africa show rising ALS awareness but uneven access, with Brazil, Mexico, GCC countries, and South Africa serving as important care hubs where specialist availability, reimbursement systems, and diagnostic pathways shape treatment continuity.

Key Group Insights: G7, EU, BRICS, ASEAN, GCC & NATO

The G7 remains central to ALS treatment innovation because the United States, Canada, Japan, Germany, France, Italy, and the United Kingdom combine advanced regulatory systems, clinical trial infrastructure, neuromuscular centers, and reimbursement pathways for high-cost orphan medicines. NATO countries overlap significantly with this innovation base and contribute to broader neurological research networks, data-sharing initiatives, rehabilitation technology adoption, and coordinated standards for advanced care delivery.

The European Union supports coordinated rare disease policy, centralized medicine evaluation, pharmacovigilance, and cross-border research collaboration, making it a key platform for ALS drug development and real-world evidence generation. BRICS countries, led by China, India, Brazil, and supported by expanding research activity in Russia and South Africa, are becoming increasingly important for patient population scale, clinical study participation, biosimilar and generic capabilities, and health system modernization. ASEAN and GCC markets are earlier in adoption but strategically relevant as specialist neurology services, medical tourism, digital health investment, and national rare disease programs expand across member countries.

Key Country Insights Across Major ALS Treatment Markets

The United States is the most influential ALS treatment environment, supported by orphan drug policy, the Accelerating Access to Critical Therapies for ALS Act, major academic centers, clinical trial networks, and advocacy-led funding. Canada follows with strong neuromuscular care networks and public coverage mechanisms, while Mexico and Brazil are improving access through public and private neurology services, although advanced therapies remain more dependent on reimbursement decisions, specialist availability, and diagnostic infrastructure.

In Europe, the United Kingdom, Germany, France, Italy, and Spain maintain active ALS research ecosystems, multidisciplinary care models, and participation in international clinical studies, while Russia's access environment is more variable across regions and care settings. China and India are expanding diagnostic capacity, neurology services, and clinical research participation; Japan has deep experience with edaravone use and aging-related neurology demand; South Korea is investing in advanced biopharma and digital health; and Australia combines rare disease governance, specialist centers, and active clinical trial participation to support high-quality ALS care.

Actionable Recommendations for ALS Treatment Industry Leaders

Industry leaders should prioritize genetically stratified development programs, validated biomarkers, and patient-centered endpoints that reflect function, survival, speech, respiratory status, caregiver burden, and quality of life. Partnerships with ALS registries, academic neuromuscular centers, clinical trial networks, and advocacy organizations can improve recruitment, retention, genetic testing access, and real-world evidence quality.

Commercial strategies should account for the full ALS care continuum, not only drug therapy. Manufacturers, medtech developers, and digital health organizations can create value by integrating therapies with remote monitoring, assistive communication, respiratory support, nutrition management, rehabilitation, and home-based care. Early payer engagement, transparent evidence packages, post-approval data generation, and equitable access planning are critical for high-cost precision therapies in amyotrophic lateral sclerosis treatment.

Research Methodology for ALS Treatment Market Analysis

This executive summary is developed using a structured secondary and analytical research approach, drawing on verified information from regulatory agencies, public health organizations, peer-reviewed neurology literature, clinical trial registries, treatment guidelines, and recognized ALS advocacy and research institutions. Key evidence inputs include treatment approvals, disease epidemiology, orphan drug frameworks, trial activity, genetic testing relevance, biomarker development, and regional healthcare access indicators.

Insights are synthesized through cross-validation of clinical, regulatory, commercial, and geographic signals. The methodology emphasizes data integrity, source reliability, market relevance, and reproducibility. No unsupported market estimates are used; qualitative conclusions are grounded in observable treatment patterns, approved therapeutic options, documented disease burden, current clinical research activity, and validated innovation trends in ALS care.

Conclusion: Future of ALS Treatment Innovation

The amyotrophic lateral sclerosis treatment market is entering a decisive phase as precision medicine, AI-enabled research, and multidisciplinary care converge. While ALS remains a devastating and rapidly progressive disease, recent advances show that genetically targeted intervention, biomarker-driven development, and integrated supportive care can change the trajectory of therapeutic innovation.

Future progress will depend on earlier diagnosis, broader genetic testing, stronger real-world evidence, equitable reimbursement, and integrated care models that connect medicines with respiratory, nutritional, mobility, speech, and palliative support. Organizations that align clinical science with patient access, digital monitoring, and global collaboration will be best positioned to improve outcomes and compete effectively in this highly specialized neurodegenerative disease market.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Amyotrophic Lateral Sclerosis Treatment Market, by Treatment

  • 7.1. Drug Type
    • 7.1.1. Edaravone
    • 7.1.2. Riluzole
  • 7.2. Therapy
    • 7.2.1. Gene Therapy
    • 7.2.2. Stem Cell Therapy

8. Amyotrophic Lateral Sclerosis Treatment Market, by Type

  • 8.1. Familial ALS
  • 8.2. Sporadic ALS

9. Amyotrophic Lateral Sclerosis Treatment Market, by Treatment Stage

  • 9.1. Early Stage Treatment
  • 9.2. Mid Stage Treatment
  • 9.3. Late Stage Treatment

10. Amyotrophic Lateral Sclerosis Treatment Market, by Route of Administration

  • 10.1. Intrathecal
  • 10.2. Intravenous
  • 10.3. Oral

11. Amyotrophic Lateral Sclerosis Treatment Market, by Line Of Therapy Strategy

  • 11.1. First-Line
  • 11.2. Targeted Therapy
  • 11.3. Second-Line/Supportive Care

12. Amyotrophic Lateral Sclerosis Treatment Market, by Patient Age Group

  • 12.1. Juvenile & Young-Adult Onset
  • 12.2. Late Onset

13. Amyotrophic Lateral Sclerosis Treatment Market, by Care Setting

  • 13.1. Inpatient Hospital
  • 13.2. Outpatient Hospital
  • 13.3. Specialty Clinics
    • 13.3.1. Multidisciplinary ALS Clinics
    • 13.3.2. Neurology Specialty Practices
  • 13.4. Home Care

14. Amyotrophic Lateral Sclerosis Treatment Market, by Distribution Channel

  • 14.1. Online
  • 14.2. Offline

15. Amyotrophic Lateral Sclerosis Treatment Market, by Region

  • 15.1. Asia-Pacific
  • 15.2. North America
  • 15.3. Latin America
  • 15.4. Europe
  • 15.5. Middle East
  • 15.6. Africa

16. Amyotrophic Lateral Sclerosis Treatment Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Amyotrophic Lateral Sclerosis Treatment Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025

19. Company Profiles

  • 19.1. Tanabe Pharma Corporation
  • 19.2. Biogen Inc.
  • 19.3. Novartis AG
  • 19.4. Amylyx Pharmaceuticals, Inc.
  • 19.5. Dewpoint Therapeutics, Inc.
  • 19.6. Zydus Lifesciences Limited
  • 19.7. Sun Pharmaceutical Industries Ltd
  • 19.8. Otsuka Pharmaceutical Co., Ltd.
  • 19.9. Sanofi SA
  • 19.10. Teva Pharmaceutical Industries Ltd.
  • 19.11. Viatris Inc.
  • 19.12. Cipla Limited
  • 19.13. F. Hoffmann-La Roche Ltd
  • 19.14. GlaxoSmithKline PLC
  • 19.15. AB Science SA
  • 19.16. Alector, Inc.
  • 19.17. Apotex Inc.
  • 19.18. Aquestive Therapeutics, Inc.
  • 19.19. AstraEureka Pharmaceuticals
  • 19.20. BrainStorm Cell Limited
  • 19.21. CorestemChemon Inc.
  • 19.22. Coya Therapeutics, Inc.
  • 19.23. Cytokinetics, Incorporated
  • 19.24. DR. REDDY'S LABORATORIES LIMITED
  • 19.25. Genervon Biopharmaceuticals, LLC
  • 19.26. Implicit Bioscience Ltd.
  • 19.27. Ionis Pharmaceuticals, Inc.
  • 19.28. ITF Pharma, Inc.
  • 19.29. Kringle Pharma, Inc.
  • 19.30. Neurimmune AG
  • 19.31. ONO PHARMACEUTICAL CO., LTD.
  • 19.32. Orion Corporation
  • 19.33. Orphazyme A/S
  • 19.34. Pfizer, Inc.
  • 19.35. Treeway B.V.

LIST OF FIGURES

  • FIGURE 1. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY LINE OF THERAPY STRATEGY, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY LINE OF THERAPY STRATEGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY CARE SETTING, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY CARE SETTING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 29. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DRUG TYPE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DRUG TYPE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRUG TYPE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL EDARAVONE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL EDARAVONE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL EDARAVONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL RILUZOLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL RILUZOLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL RILUZOLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL STEM CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL FAMILIAL ALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL FAMILIAL ALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL FAMILIAL ALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SPORADIC ALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SPORADIC ALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SPORADIC ALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL EARLY STAGE TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL EARLY STAGE TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL EARLY STAGE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MID STAGE TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MID STAGE TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MID STAGE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LATE STAGE TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LATE STAGE TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL LATE STAGE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INTRATHECAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INTRATHECAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INTRATHECAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY LINE OF THERAPY STRATEGY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL FIRST-LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL FIRST-LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL FIRST-LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TARGETED THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SECOND-LINE/SUPPORTIVE CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SECOND-LINE/SUPPORTIVE CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SECOND-LINE/SUPPORTIVE CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL JUVENILE & YOUNG-ADULT ONSET MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL JUVENILE & YOUNG-ADULT ONSET MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL JUVENILE & YOUNG-ADULT ONSET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL LATE ONSET MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL LATE ONSET MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL LATE ONSET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL INPATIENT HOSPITAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL INPATIENT HOSPITAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL INPATIENT HOSPITAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL OUTPATIENT HOSPITAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL OUTPATIENT HOSPITAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL OUTPATIENT HOSPITAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MULTIDISCIPLINARY ALS CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MULTIDISCIPLINARY ALS CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MULTIDISCIPLINARY ALS CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NEUROLOGY SPECIALTY PRACTICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEUROLOGY SPECIALTY PRACTICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NEUROLOGY SPECIALTY PRACTICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HOME CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HOME CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HOME CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY LINE OF THERAPY STRATEGY, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY LINE OF THERAPY STRATEGY, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY LINE OF THERAPY STRATEGY, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY LINE OF THERAPY STRATEGY, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY LINE OF THERAPY STRATEGY, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY LINE OF THERAPY STRATEGY, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY LINE OF THERAPY STRATEGY, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. GCC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 178. GCC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 179. GCC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. GCC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 181. GCC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. GCC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 183. GCC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 184. GCC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY LINE OF THERAPY STRATEGY, 2018-2032 (USD MILLION)
  • TABLE 185. GCC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. GCC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 187. GCC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 188. GCC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY LINE OF THERAPY STRATEGY, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY LINE OF THERAPY STRATEGY, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 213. G7 AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 214. G7 AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 215. G7 AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. G7 AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 217. G7 AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. G7 AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 219. G7 AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 220. G7 AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY LINE OF THERAPY STRATEGY, 2018-2032 (USD MILLION)
  • TABLE 221. G7 AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 222. G7 AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 223. G7 AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 224. G7 AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. NATO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 226. NATO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 227. NATO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. NATO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 229. NATO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. NATO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 231. NATO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 232. NATO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY LINE OF THERAPY STRATEGY, 2018-2032 (USD MILLION)
  • TABLE 233. NATO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 234. NATO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 235. NATO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 236. NATO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY LINE OF THERAPY STRATEGY, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 250. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 251. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 252. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 254. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 256. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 257. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY LINE OF THERAPY STRATEGY, 2018-2032 (USD MILLION)
  • TABLE 258. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 259. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 260. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 261. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 262. MEXICO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 263. MEXICO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 264. MEXICO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. MEXICO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 266. MEXICO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. MEXICO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 268. MEXICO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 269. MEXICO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY LINE OF THERAPY STRATEGY, 2018-2032 (USD MILLION)
  • TABLE 270. MEXICO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 271. MEXICO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 272. MEXICO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 273. MEXICO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 274. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 275. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 276. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 278. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 280. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 281. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY LINE OF THERAPY STRATEGY, 2018-2032 (USD MILLION)
  • TABLE 282. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 283. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 284. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 285. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED KINGDOM AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED KINGDOM AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED KINGDOM AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED KINGDOM AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED KINGDOM AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED KINGDOM AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED KINGDOM AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED KINGDOM AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY LINE OF THERAPY STRATEGY, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED KINGDOM AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED KINGDOM AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED KINGDOM AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED KINGDOM AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 298. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 299. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 300. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 302. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 303. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 304. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 305. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY LINE OF THERAPY STRATEGY, 2018-2032 (USD MILLION)
  • TABLE 306. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 307. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 308. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 309. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 310. FRANCE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 311. FRANCE AMYOTROPHIC L